(1 - 11 von 13
)
EQS-News: Formycon AG: Formycon und Fresenius Kabi ...Finanznachrichten
www.finanznachrichten.de
— ... Biosimilars zu ermöglichen," ergänzt Dr. Michael Schönhofen, Chief Operating Officer und Mitglied des Vorstands der Fresenius Kabi AG.
EQS-News: Formycon and Fresenius Kabi conclude global ...Bloomberg
www.bloomberg.com
— ... worldwide,” says Dr. Michael Schönhofen, Fresenius Kabi's Chief Operating Officer and Member of the Fresenius Kabi Management Board.
EQS-News: Formycon und Fresenius Kabi schließen ...Onvista
www.onvista.de
— ... Patienten weltweit Zugang zu Biosimilars zu ermöglichen,“ ergänzt Dr. Michael Schönhofen, Chief Operating Officer und Mitglied des ...
Fresenius Kabi Receives U.S. FDA Approval for Biosimilar ...AP News
apnews.com
— Dr. Michael Schönhofen, Fresenius Kabi's Chief Operating Officer and Member of the Fresenius Kabi Management Board, said: “The FDA approval ...
sortiert nach Relevanz / Datum